Prevnar 20 (Pfizer) is expected to face US follow-on vaccine competition from 2035. Pfizer 10-K: US basic product patent expires 2035. Sales are the whole Prevnar family.
Prevnar 20's US exclusivity date is based on company guidance. The date comes from the company's own filings or guidance. Secondary patents, new formulations or litigation can still move it. It is a vaccine. Vaccines are hard to copy, so competition after patents expire usually arrives slowly.
Prevnar 20 is 10% of Pfizer's 2025 revenue ($6.5B of $62.6B). With Ibrance, Xtandi and Eliquis, the drugs tracked here add up to 33% of Pfizer's revenue losing US exclusivity by 2035. Eliquis and Xtandi are Pfizer's reported alliance and product revenue ($8.0B, $2.2B).
Bars show each company's tracked drugs as a share of its total 2025 revenue. Prevnar 20 is highlighted.